Press release
Bone Metastasis Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Bone Metastasis Treatment Landscape. @ Bone Metastasis Pipeline Outlook [https://www.delveinsight.com/sample-request/bone-metastasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bone Metastasis Pipeline Report
* On April 20, 2026- Washington University School of Medicine initiated a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
* On April 20, 2026- VA Office of Research and Development conducted a study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur
* On April 13, 2026- Eli Lilly and Company announced a phase 2 study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer.
* DelveInsight's Bone Metastasis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Bone Metastasis treatment.
* The leading Bone Metastasis Companies such as Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc., BiologicsMD, Luye Pharma Group Ltd., QSAM Biosciences Inc., Serene, LLC, Isotopen Technologien Munchens and others.
* Promising Bone Metastasis Pipeline Therapies such as Radium Ra 223 Dichloride, MW032, Xgeva, Zoledronic Acid, Radium-223 chloride (BAY88-8223), Pamidronate, Docetaxel and others.
Discover groundbreaking developments in Bone Metastasis Therapies! Gain in-depth knowledge of key Bone Metastasis clinical trials, emerging drugs, and market opportunities @ Bone Metastasis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bone-metastasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bone Metastasis Emerging Drugs Profile
* MW032: Mabwell (Shanghai) Bioscience Co., Ltd.
MW032 is a Denosumab biosimilar being developed by Mabwell (Shanghai) Bioscience Co., Ltd. Denosumab is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. MW032 is currently in Phase III stage of development to treat Bone Metastases from Solid Tumors.
* ALMB-0168: AlaMab Therapeutics
ALMB-0168 is a first-inclass humanized monoclonal antibody agonist for hemichannel Cx43 membrane protein. Through the activation of Cx43 protein to release tumor-inhibiting cytokines, ALMB-0168 has shown to effectively inhibit osteosarcoma and bone metastasis in pre-clinical in vitro and in vivo animal studies. ALMB-0168 has received Orphan Disease Drug and Rare Pediatric Disease designations from the FDA for its use in osteosarcoma.
The Bone Metastasis Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Bone Metastasis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bone Metastasis Treatment.
* Bone Metastasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Bone Metastasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bone Metastasis market
Stay informed about the Bone Metastasis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Bone Metastasis Unmet Needs [https://www.delveinsight.com/sample-request/bone-metastasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bone Metastasis Companies
Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc., BiologicsMD, Luye Pharma Group Ltd., QSAM Biosciences Inc., Serene, LLC, Isotopen Technologien Munchens and others.
Bone Metastases Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Bone Metastasis Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Transform your understanding of the Bone Metastasis Pipeline! See the latest progress in drug development and clinical research @ Bone Metastasis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bone-metastasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bone Metastasis Pipeline Report
* Coverage- Global
* Bone Metastasis Companies- Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc., BiologicsMD, Luye Pharma Group Ltd., QSAM Biosciences Inc., Serene, LLC, Isotopen Technologien Munchens and others.
* Bone Metastasis Pipeline Therapies- Radium Ra 223 Dichloride, MW032, Xgeva, Zoledronic Acid, Radium-223 chloride (BAY88-8223), Pamidronate, Docetaxel and others.
* Bone Metastasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bone Metastasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Research-Access the Full Bone Metastasis Pipeline Analysis Today! @ Bone Metastasis Drugs and Companies [https://www.delveinsight.com/sample-request/bone-metastasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Bone Metastases: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bone Metastases - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* MW032: Mabwell (Shanghai) Bioscience Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Cabozantinib: Exelixis
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ALMB-0168: AlaMab Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* BMD 3151: BiologicsMD
* Drug profiles in the detailed report.....
* Inactive Products
* Bone Metastases Key Companies
* Bone Metastases Key Products
* Bone Metastases- Unmet Needs
* Bone Metastases- Market Drivers and Barriers
* Bone Metastases- Future Perspectives and Conclusion
* Bone Metastases Analyst Views
* Bone Metastases Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bone-metastasis-treatment-pipeline-shows-strong-momentum-as-10-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-metastasis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bone Metastasis Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight here
News-ID: 4491564 • Views: …
More Releases from ABNewswire
Prince Health Offers Advanced Hyperbaric Oxygen Therapy in The Woodlands Texas f …
Prince Health in The Woodlands, TX, introduces the Houston area's largest multi-person Hyperbaric Oxygen Therapy (HBOT) chamber. This spacious, state-of-the-art facility eliminates claustrophobia, offering non-invasive, cellular-level healing. The new HBOT services provide holistic, drug-free relief for patients recovering from Long COVID, chronic pain, physical trauma, and neurological conditions, accelerating tissue repair and reducing systemic inflammation.
THE WOODLANDS, TX - Prince Health [https://princehealth.org/], a leading integrative wellness clinic, is redefining holistic recovery…
Chef Eddie G Introduces Locavore Pods While Continuing Culinary Media and Educat …
Image: https://www.abnewswire.com/upload/2026/04/9ab13a375aa6f32e3966d77ed0ba94e2.jpg
Chef Eddie G, a culinary professional and media personality, is continuing to expand his work across food storytelling, culinary education, and early-stage platform development. Through his official website, ChefEddieG.TV, Chef Eddie G brings together his culinary background, television projects, and educational initiatives while also participating in the development of Locavore Pods [http://locavorepods.com/], a new project currently under construction at LocavorePods.com.
The initiatives reflect an ongoing focus on local food culture,…
Cancos Tile & Stone Launches Memorial Day Sales Event
The company is offering up to 40% Off Tile & 15% Off Fabrication
Image: https://www.abnewswire.com/upload/2026/04/4dea04c6095697cb9645e0d149aed5a0.jpg
Long Island, NY - Cancos Tile & Stone, a trusted leader in tile, stone, and design solutions for over 70 years, is proud to announce its Memorial Day Sales Event, offering exceptional savings on premium materials for a limited time.
Running from May 4 through May 25, this three-week event is designed to help homeowners, contractors, and designers…
Book Launch Spotlight: Dr. Dorothy Borders Offers Media Interviews on How Life's …
Chicago, IL - May 1, 2026 - Dr. Dorothy Borders, author of the newly released book The Dead End , is available for interviews to discuss the transformative power of life's setbacks and how they can lead to new beginnings.
In her book, Dr. Borders shares how moments of stagnation and struggle are not signs of failure but opportunities for spiritual growth and redirection. By embracing God's calling at the crossroads…
More Releases for Bone
Bone Densitometers (BDM): Precise Assessment of Bone Health and Osteoporosis Ris …
Bone Densitometers(BDM) Market 2023 Forecast: Unveiling Opportunities and Growth
Bone Densitometers(BDM) Market research report helps to recognize the market challenges and opportunities. Global Bone Densitometers(BDM) Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of every area including the volume of…
Demineralized Bone Matrix Market - A Natural Approach to Bone Repair: Deminerali …
Newark, New Castle, USA: The "Demineralized Bone Matrix Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Demineralized Bone Matrix Market: https://www.growthplusreports.com/report/demineralized-bone-matrix-market/7805
This latest report researches the industry structure,…
Bone Glue Market: Rising Adoption of Bone Glue for Orthopedic Surgeries Expected …
The Bone Glue Market is a rapidly growing segment of the medical industry, driven by the increasing prevalence of bone fractures and injuries and the rising demand for effective and reliable bone adhesives. Bone glue, also known as surgical adhesive, is a type of medical adhesive that is used to bond bones together during orthopedic surgeries. The market has been growing steadily for several years, and it is expected to…
Bone Glue Market: Rising Adoption of Bone Glue for Orthopedic Surgeries Expected …
The Bone Glue Market is a rapidly growing segment of the medical industry, driven by the increasing prevalence of bone fractures and injuries and the rising demand for effective and reliable bone adhesives. Bone glue, also known as surgical adhesive, is a type of medical adhesive that is used to bond bones together during orthopedic surgeries. The market has been growing steadily for several years, and it is expected to…
Bone Glue Market: Rising Adoption of Bone Glue for Orthopedic Surgeries Expected …
The Bone Glue Market is a rapidly growing segment of the medical industry, driven by the increasing prevalence of bone fractures and injuries and the rising demand for effective and reliable bone adhesives. Bone glue, also known as surgical adhesive, is a type of medical adhesive that is used to bond bones together during orthopedic surgeries. The market has been growing steadily for several years, and it is expected to…
Bone Graft Substitute Market Report 2018: Segmentation by Type (autograft, demin …
Global Bone Graft Substitute market research report provides company profile for ACE Surgical Supply Company, Inc., BioHorizons IPH, Inc., Dentium Co., Ltd., Dentsply Sirona, Institut Straumann AG, Medtronic plc, Stryker Corporation, Zimmer Biomet and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and…
